阿司匹林在老年人中的心血管事件与大出血:ASPREE试验延长随访
本研究基于ASPREE试验的试验期(2010-17)与试验后(2017-22)延长随访数据,分析无心血管事件、痴呆或限制独立生活残疾的≥70岁(美国少数族裔≥65岁)老年人每日低剂量阿司匹林随机治疗的长期效应。
要点
- 试验后期间,阿司匹林组MACE发生率高于安慰剂组(HR 1.17,95%CI 1.01-1.36)。
- 整个期间阿司匹林组大出血发生率更高(HR 1.24,95%CI 1.10-1.39)。
核心结论
- 在初始健康的老年人中,随机分配至低剂量阿司匹林对整个试验期及试验后期间MACE无长期获益,且大出血风险更高。
- 试验后期间阿司匹林组MACE发生率更高,该发现需在临床决策中考虑。
研究设计与样本
- ASPREE试验延长随访分析,纳入试验期(2010-17)及试验后(2017-22)数据。
- 入组时年龄≥70岁(美国少数族裔≥65岁),无既往心血管事件、痴呆或限制独立生活的身体残疾。
- 随机分配至每日低剂量阿司匹林或匹配安慰剂,试验期4.7年。
- 共随机19 114例(阿司匹林9525例,安慰剂9589例),其中15 668例无试验期MACE者同意试验后随访。
主要发现
- 试验后期间(中位4.3年),阿司匹林组MACE发生率高于安慰剂组(HR 1.17,95%CI 1.01-1.36)。
- 整个期间,阿司匹林组大出血发生率高于安慰剂组(HR 1.24,95%CI 1.10-1.39)。
临床怎么用
- 在考虑对初始健康老年人使用阿司匹林进行一级预防时,应权衡无长期MACE获益与大出血风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Guidelines recommend against routine initiation of low-dose aspirin in older adults for primary prevention of atherosclerotic cardiovascular disease events. This study aimed to estimate long-term and post-trial effects of aspirin on major adverse cardiovascular events (MACE) and major haemorrhage using extended follow-up of participants from the ASPREE trial. METHODS: In-trial (2010-17) and post-trial (2017-22) data were analysed. At enrolment, participants were aged ≥70 years (≥65 years for US minorities) without prior cardiovascular events, dementia, or independence-limiting physical disability. Randomization was to daily low-dose aspirin or matching placebo for the 4.7 years of the trial. RESULTS: Of the 19 114 participants randomized (9525 aspirin, 9589 placebo), 15 668 without in-trial MACE consented to post-trial follow-up. No long-term benefit of randomization to aspirin was observed for MACE for the entire in-trial and post-trial period [hazard ratio (HR) 1.04, 95% confidence interval (CI) .94, 1.15]. However, during the post-trial period (median 4.3 years), there was a higher rate of MACE (HR 1.17, 95% CI 1.01, 1.36) in those randomized to aspirin compared with placebo. Over the entire period, a higher rate of major haemorrhage was observed in the randomized aspirin group compared with placebo (HR 1.24, 95% CI 1.10, 1.39). CONCLUSIONS: The present study provides novel evidence concerning long-term MACE and haemorrhage following aspirin use in initially healthy older adults. The finding of no long-term MACE benefit needs to be considered in clinical decision-making if aspirin is being considered for use in this context.
引用
- Wolfe R, Broder JC, Zhou Z, et al. Aspirin, cardiovascular events, and major bleeding in older adults: extended follow-up of the ASPREE trial. Eur Heart J. 2025. PMID: 40796244. doi:10.1093/eurheartj/ehaf514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。